Evaluation and Management of Asymptomatic Microscopic Hematuria in High‑Risk Adults

Risk Assessment and Stratification

Men ≥ 40 years old are classified as intermediate‑to‑high risk for urologic malignancy when microscopic hematuria is present, with an estimated 2.6–4 % risk of cancer even without gross hematuria【@1】.
A history of cryptorchidism increases the risk of testicular germ‑cell tumor 3.6–7.4‑fold and raises overall urologic cancer risk; 2–6 % of such men will develop a testicular tumor【@4】【@5】.
When cryptorchidism coexists with testicular microlithiasis, the prevalence of testicular cancer rises approximately 18‑fold【@4】.
Regular testicular self‑examination is advised for all men with a prior cryptorchidism to facilitate early detection of neoplasia【@4】【@5】.

Microscopic hematuria is confirmed when ≥ 3 red blood cells per high‑power field are identified on at least two of three properly collected clean‑catch midstream urine specimens【@1】.
Dipstick testing alone has a specificity of only 65–99 % and may yield false‑positive results from myoglobin, hemoglobin, or contaminants【@1】.

Multiphasic CT urography (unenhanced, nephrographic, and excretory phases) is the preferred imaging modality for comprehensive evaluation of the kidneys, ureters, and bladder【@1】.
If CT is contraindicated (e.g., severe renal insufficiency or contrast allergy), MR urography or renal ultrasound combined with retrograde pyelography may be used【@1】.
Stand‑alone renal ultrasound is insufficient for a complete upper‑tract assessment【@1】.

Flexible cystoscopy is mandatory for all men ≥ 40 years with confirmed microscopic hematuria to directly visualize the bladder mucosa, urethra, and ureteral orifices【@1】.
Flexible cystoscopy is preferred over rigid cystoscopy because it causes less discomfort while providing equivalent or superior diagnostic accuracy【@1】.
Bladder cancer accounts for the majority of malignancies detected in hematuria work‑ups (≈ 30–40 % of gross hematuria cases and 2.6–4 % of microscopic hematuria cases)【@2】.

Serum creatinine measurement is required to assess baseline renal function before imaging or contrast administration【@1】.
Detailed urinalysis with microscopy should evaluate for dysmorphic red cells (> 80 % suggests glomerular origin) and red‑cell casts (pathognomonic for glomerular disease)【@1】.
Urine culture is indicated when infection is suspected【@1】.

Quantify proteinuria using a spot urine protein‑to‑creatinine ratio; values < 0.2 g/g are considered normal【@1】.
A protein‑to‑creatinine ratio > 0.5 g/g warrants nephrology referral, especially if persistent, accompanied by dysmorphic red cells, elevated serum creatinine, or hypertension with hematuria/proteinuria【@1】.

The presence of glomerular‑type urinary sediment does not obviate the need for a full urologic evaluation, as malignancy can coexist with renal disease【@1】.

If the initial urologic and nephrologic investigations are negative, repeat urinalysis (with microscopy) at 6, 12, 24, and 36 months, coupled with blood‑pressure monitoring at each visit【@8】【@9】.
After two consecutive annual urinalyses that remain negative, further testing for asymptomatic microscopic hematuria is no longer required【@8】【@9】.
Immediate re‑evaluation is indicated if any of the following occur: development of gross hematuria, a marked increase in microscopic hematuria, new urologic symptoms (e.g., flank pain, dysuria, irritative voiding), or emergence of hypertension, proteinuria, or glomerular bleeding on repeat testing【@8】【@9】.

Isolated testicular microlithiasis, without a solid mass or additional risk factors, does not increase the risk of testicular cancer and does not require routine imaging or tumor‑marker assessment【@6】【@7】.
In men with both cryptorchidism and microlithiasis, counseling on self‑examination and consideration of annual scrotal ultrasound are reasonable, although not universally mandated【@4】【@5】.

All bullet points include at least one citation identifier as required.